Zymeworks Inc. has disclosed a notable stock transaction involving its Chief Business Officer, Scott Platshon. The filing reveals that Platshon acquired and sold shares of the company's stock, highlighting ongoing financial activities within the organization.

This event is significant as it illustrates the company's commitment to managing its equity structure effectively. The transactions were executed on November 18, 2026, and they reflect the dynamic nature of the pharmaceutical preparations industry.

Background

Zymeworks Inc., trading under the ticker symbol ZYME on the Nasdaq, is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is based in Middletown, Delaware, and operates as a smaller reporting company, focusing on innovative life sciences solutions.

What the Filing Says

According to the recent SEC filing, Platshon reported two key transactions. He acquired 37,037 shares of common stock, which were issued upon the vesting of restricted stock units (RSUs) granted on November 18, 2025. Additionally, he sold 15,292 shares to cover tax withholding obligations related to this vesting. The sale was executed at a weighted average price of $24.95 per share.

Impact

This update may impact various stakeholders, including investors and employees. The stock transactions reflect the financial strategies employed by the company's executives, which can influence investor sentiment and perceptions of the company's stability. Furthermore, the sale of shares to cover tax obligations indicates a proactive approach to managing personal financial responsibilities tied to stock compensation.

What's Next

The filing does not say what happens next.